Wugen Enters into License Agreement with Washington University for its CAR-T Therapy Technologies

 Wugen Enters into License Agreement with Washington University for its CAR-T Therapy Technologies

Wugen Enters into License Agreement with Washington University for its CAR-T Therapy Technologies

Shots:

  • Wugen to get exclusive & IPR rights for CAR-T Technologies developed by Washington University
  • The focus of the agreement is to develop and commercialize novel CAR-T therapies to treat blood cancer
  • The novel CAR-T therapy platform including fratricide-resistant “off-the-shelf” system, targeting CD7+ T cell malignancies

Click here to read full press release/ article | Ref: PRNewswire | Image: The Business Journals

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post